L A Emens1, S Adams2, C H Barrios3, V Diéras4, H Iwata5, S Loi6, H S Rugo7, A Schneeweiss8, E P Winer9, S Patel15, V Henschel11, A Swat12, M Kaul13, L Molinero14, S Patel15, S Y Chui10, P Schmid16. 1. University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, USA. Electronic address: emensla@upmc.edu. 2. New York University Langone Health, Perlmutter Cancer Center, New York, USA. 3. Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil. 4. Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. 5. Aichi Cancer Center Hospital, Nagoya, Japan. 6. Peter MacCallum Cancer Centre, Melbourne, Australia. 7. University of California San Francisco Comprehensive Cancer Center, San Francisco, USA. 8. University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany. 9. Dana-Farber Cancer Institute, Boston, USA. 10. Genentech, Inc., South San Francisco, USA. 11. F. Hoffmann-La Roche Ltd., Basel, Switzerland. 12. Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland. 13. Product Development Safety, Genentech, Inc., South San Francisco. 14. Oncology Biomarker Development, Genentech, Inc., South San Francisco. 15. Product Development Data Sciences, Genentech, Inc., South San Francisco, USA. 16. Barts Cancer Institute, Queen Mary University London, London, UK.
Abstract
BACKGROUND: Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. PATIENTS AND METHODS: Patients were randomized to nP 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population). RESULTS: Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively. CONCLUSION: Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.
RCT Entities:
BACKGROUND: Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. PATIENTS AND METHODS: Patients were randomized to nP 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population). RESULTS: Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively. CONCLUSION: Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.
Authors: Vladimir Semiglazov; Andrey Tseluiko; Asel Kudaybergenova; Anna Artemyeva; Petr Krivorotko; Roman Donskih Journal: Cancer Biol Med Date: 2022-06-09 Impact factor: 5.347
Authors: Christiane Klec; Erik Knutsen; Daniela Schwarzenbacher; Katharina Jonas; Barbara Pasculli; Ellen Heitzer; Beate Rinner; Katarina Krajina; Felix Prinz; Benjamin Gottschalk; Peter Ulz; Alexander Deutsch; Andreas Prokesch; Stephan W Jahn; S Mohammad Lellahi; Maria Perander; Raffaela Barbano; Wolfgang F Graier; Paola Parrella; George Adrian Calin; Martin Pichler Journal: Cell Mol Life Sci Date: 2022-07-01 Impact factor: 9.207
Authors: Ashley V DiMarco; Xiaodi Qin; Brock J McKinney; Nina Marie G Garcia; Sarah C Van Alsten; Elizabeth A Mendes; Jeremy Force; Brent A Hanks; Melissa A Troester; Kouros Owzar; Jichun Xie; James V Alvarez Journal: Cancer Immunol Res Date: 2021-11-18 Impact factor: 12.020
Authors: Sylvia Adams; Megan Othus; Sandip Pravin Patel; Kathy D Miller; Rashmi Chugh; Scott M Schuetze; Mary D Chamberlin; Barbara J Haley; Anna Maria V Storniolo; Mridula P Reddy; Scott A Anderson; Collin T Zimmerman; Anne P O'Dea; Hamid R Mirshahidi; Jordi Rodon Ahnert; Frank J Brescia; Olwen Hahn; Jane M Raymond; David D Biggs; Roisin M Connolly; Elad Sharon; Larissa A Korde; Robert J Gray; Edward Mayerson; Melissa Plets; Charles D Blanke; Young Kwang Chae; Razelle Kurzrock Journal: Clin Cancer Res Date: 2021-10-29 Impact factor: 13.801